NewAmsterdam Pharma Company Stock News
$23.65
2.23%
today
Nasdaq,
Sep 15, 03:55 pm CET
Industry
NewAmsterdam Pharma Company Stock News
Neutral
Seeking Alpha
●
11 days ago
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS ) Citi's Biopharma Back to School Conference September 3, 2025 2:30 PM EDT Company Participants Michael Davidson - CEO, President & Executive Board Member Mayur Somaiya - Chief Financial Officer Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director All right.
Neutral
GlobeNewsWire
●
21 days ago
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
NAARDEN, The Netherlands and MIAMI, Aug. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not suff...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
